Penn Medicine Co-Investment Program
VC Fund
Philadelphia, United States
Penn Medicine Co-Investment Program is a VC fund in Philadelphia focused on Health Care and Biotechnology. Penn Medicine Co-Investment Program makes investments in faculty-driven cell therapy, gene therapy, and connected health companies
- Total investments:
- 19
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Penn Medicine Co-Investment Program invests in
Stages Penn Medicine Co-Investment Program invests in
Countries Penn Medicine Co-Investment Program invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carter Caldwell
|
|||
Investment Focus
Industry
- Health Care 7 (37%)
- Biotechnology 7 (37%)
- Therapeutics 5 (26%)
- Medical 4 (21%)
- Manufacturing 2 (11%)
Stage
- Seed 5 (26%)
- Series A 5 (26%)
- Series B 4 (21%)
- Funding Round 2 (11%)
- Series C 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Carter Caldwell
Program Director
|
Program Director | Total investments: 16 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M / Jan 01, 2025 | |
BlueWhale Bio
|
BlueWhale Bio is spinout from the University of Pennsylvania to accelerate the use of cell-based therapies by manufacturing innovation. | $18M / Seed / Sep 07, 2023 | |
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M / Series C / Sep 21, 2022 | |
Innervace
|
Innervace is a developer of a regenerative therapy company designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders.The company is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction, and its lead clinical product is a tissue-engineerednigrostriatal pathway that mimics the lost nigrostriatal pathway in patients with Parkinson's disease. This gives patients access to technology that specifically reconstructs brain pathways rather than just masking symptoms temporarily.Innervace was established in 2018 by in Philadelphia, Pennsylvania | $40M / Series A / Sep 08, 2022 | |
Vittoria Biotherapeutics
|
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings. | $10M / Seed / Jun 07, 2022 | |
CareAlign
|
CareAlign provides clinicians with an intuitive, patient-centric task management tool to track, manage and coordinate clinical care. Easily assign, date and time tasks, categorize them for when they are due, view cleared tasks and more. | $2.3M / Seed / Nov 30, 2021 | |
|
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $76M / Series A / May 18, 2021 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M / Series B / Mar 01, 2021 | |
|
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $5.5M / Mar 13, 2020 | |
|
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $5.5M / Seed / Mar 13, 2020 | |
| See all 19 investments → | |||
Co-Investors
Agent Capital
8 deals together
Tellus BioVentures
5 deals together
HealthCap
4 deals together
AbbVie
3 deals together
BrightEdge Fund
3 deals together
IP Group
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Penn Medicine Co-Investment Program invest in?
Penn Medicine Co-Investment Program invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Penn Medicine Co-Investment Program?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Penn Medicine Co-Investment Program?
The team at Penn Medicine Co-Investment Program includes Carter Caldwell (Program Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
